Combined thromboxane A2synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations  by Yao, Sheng-Kun et al.
JACC Vol. 16. -No. 3 
From the Departmems of internal Medicine Kardiology Division) and Path- 
ology. University of Texas Southwestern Medical Center. Dallas and the Universily 
of Texas Medical School and the Texas Wean Institute. on. Texas. This work 
was supported in pail by N HLBI lscbemic SCQR Grant 64Qfrom the National 
Heart. Lung,and Blood Jnstilute. National Institutesof kdllh. Bethesda. Maryland 
and ial assistance from the Moss Heart Fund. Dallas. 
script received December IX, 1989: revised manuscript received 
February 22, 1990, accepted March 14, 1990. 
Address for reo&: James T. Willerson. MD. Department of lnrernal 
Medicine, University of Texas Health Science Center. PO Box 207OK 
Houston, Texas 77225. 
01990 by the American Colleg cf Cardiology 
e~“~er~ve~ factors 
ected acute coronary a 
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accumulate on the coronary rtery wd at sites wi 
thelial injury and stenosis an release va~bus facmrs, some 
of which can further activate latelets, initiate i~trac~ro~ary 
thrombosis, increase coronary artery vascular tone an 
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severely reduce blood flow to the myocardium. In addition. 
plasma hormones such as epincphrine may enhance Platelet 
aggregation (6-10). which may also contribute to the devel- 
opment of adverse clinical events. 
cyclic coronary artery flow variations were initially de- 
scribed by Felts et al. (I I, 12) and are caused by spontaneous 
platelet aggregation and dislodgment on a coronary artery 
wall (hat has severe stenosis and endothelial injury. Studies 
from our laboratory (13-17) have shown that thromboxane 
A7 is an important mediator of cyclic flow variations. Both 
thromboxane A, synthetase inhibition and thromboxane 
A,-prostaglandin Hz receptor antagonism are effective in 
eliminating cyclic flow variations (13.15). However, admin- 
istration of epinephrine r stores the cyclic flow variations 
abolished by a thromboxane A1receptor antagonist (9). 
Prostacyclin is an endothelium-derived substance with 
antiplatelet properties (18-20. When thromboxane AZsyn- 
thesis is blocked, cyclic enaoperoxides. the precursors of
both thromboxane A1and prostacyclin. accumulate and may 
be redirected toward the synthesis of prostacyclin and 
platelet inhibitor prostaglandin Dz (2I ,22). Unfortunately. 
the accumulation of cyclic endoperoxides may also act on 
the thromboxane Al receptor directly and cause platelet 
aggregation (23). The combination of a thromboxane Al 
synthetase inhibitor and a receptor antagonist has been 
shown to be more effective than either one alone inprevent- 
ing thrombosis insome experimental models (24-26). 
In this study, we used R 68.070, a dual thromboxane A2
synthetase inhibitor and thromboxane A?-prostaglandin H2 
receptor antagonist (27,28), in a canine model with cyclic 
flow variations totest he following hypotheses: I) combined 
actions of thromboxane Az synthetase inhibition and recep- 
tor blockade may be more effective ineliminating cyclic flow 
variations than either action alone; 2)these combined ac- 
tions may provide protection against epinephrine-induced 
cyclic flow variations: and 3) prostacyclin may be a contrib- 
uting factor in preventing both spontaneous and epinephrine- 
induced cyclic flow variations when the combined actions of 
thromboxane synthetase inhibition and receptor antagonism 
are used in the canine model. 
Surgical preparation. Mongrel dogs of either gender (24 
to 36 kg in weight) were anesthetized with sodium pentobar- 
bital (30 mgikg body weight) and ventilated with a mechan- 
ical respirator. A catheter was placed into the carotid artery 
for aortic pressure monitoring and two other catheters into 
jugular veins for drug administration. A fifth left intercostal 
space thoracotomy was performed and the heart was sus- 
pended in a pericardial cradle. A 1 to 2 cm segment ofthe left 
anterior descending coronary artery was gently isolated. A
pulsed Doppler flow probe was placed around the exposed 
ieft anterior descending coronary artery segment. 
When instrumentation was co 
pleted, dogs were allowed to stabilize for approximately 
30 min. Hemodynamic variables including heart rate, aortic 
pressure and coronary blood flow velocity were continu- 
ously recorded on a multichannel recorder ( 
Hewlett-Packard). Cyclic flow variations were induced by 
establishing coronary artery stenosis at a site with endothe- 
lial injury. Cushioned forceps were used to gently squeeze 
the exposed left anterior descending coronary artery seg 
ment distal to the Doppler flow probe. A hard cylindric 
plastic onstrictor was then pl around the artery at this 
site to reduce flow velocity to oximately 60% b’f control 
values. This eliminated the h mic reaction after 10 s of 
coronary artery occlusion. Once yclic 
observed, they were monitored and re 
30 min. Dogs were then treated with the 
(ions to test our hypotheses. 
Group I. Seventeen dogs were ated with SQ 29,548, a 
thromboxane A,-prostaglandin z receptor antagonist 
(Squibb Institute for Medical Research) (29). A dose of 
0.2 mglkg given by intravenous bolus injection was followed 
by a 0.2 mg/kg per h continuous intravenous infusion; if 
cyclic flow variations were not abolished, ana 
or two intravenous bolus injections of 0.2 mg/kg were given. 
After cyclic flow variations were abolished, a continuous 
intravenous infusion of epinephrine was started and in- 
creased stepwise at 1.53, 3.82, 7.64, 15.3 and 38.2 pglmin 
until cyclic flow variations were restored. Dogs were then 
monitored for 30 min with the epinepbrine infusion at the 
rate that restored cyclic fiow variations. 
Group II. Eleven dogs were treated with dazoxiben, a 
selective thromboxane AZ synthetase inhibitor (Pfizer Cen- 
tral Research) (30). The first dose was a 2.5 mglkg intrave- 
nous bolus injection followed by a 2.5 mg/kg per h continu- 
ous infusion. If cyclic flow variations were not abolished, a 
second bolus injection of 2.5 mg/kg was given. Epinephrine 
was administered in the same manner as described for Group 
I. When cyclic flow variations were restored, LY 53,857, a
serotonin Sz receptor antagonist (Eli Lilly) (3 I), was given as 
a 0.1 mglkg intravenous bolus injection with a continuous 
infusion of 0.05 mglkg per h. An additional bolus injection of 
0.05 mglkg was given if the epinephrine-induced cyclic flow 
variations were not abolished. Thirty minutes after cyclic 
flow variations were abolished, epinephrine was infused and 
increased as necessary torestore cyclic flow variations. 
Group ID. Eleven dogs were treated with R 68,070, a
dual thromboxane A, synthetase inhibitor and thromboxane 
A,-prostaglandin Hz receptor blocking agent (Janssen Re- 
search Foundation) (27,281. An intravenous bolus injection 
of 5 mg/kg with a 2 mg/kg per h continuous infusion was 
administered. After cyclic flow variations were abolished, a 
continuous intravenous infusion of e~ine~hri~e was given 
and increased as necessary to restore cyclic flow variations 
as just described. When cyciic flow variations were restored 
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measured in three dogs in 
Blood samples were ta 
ations and 30 min after 
goes. All values w 
r Student-Newman-Keul test (SAS, SAS hnstitutel. ,4 
value <O.Q5 was considered significant. 
The 45 dogs in the four groups had an average phasic 
coronary flow reduction to approximately 63 rf: 5% of control 
values and mean flow reduction to 77 t 3% of control values 
after placement of the coronary artery constrictor. There 
were no significant differences in the severity of the coronary 
stenoses among the groups. The frequency of initial cyclic 
s similar in the four grou 
w variations, as indicate 
1. Cyclic flow 
variations were abolished in I2 (71%) of the 17 dogs in Group 
I after the administration of SQ 29,548. The average bolus 
injection was 0.25 -t 0.03 mgkg in dogs with abolished cyclic 
flow variations; others received 0.6 mglkg each, but cyclic 
Gmup I Gmupll Group III Group IV 
ow variation KFV 1 arioa rate after admin- 
sla~~a~di~ W2 receptor 
box~ne A, synthetase 
romboxane A, synthetase 
IBE and aspirin and 
ow variations were a 
%‘o) within several 
= 0.06 co 
three dogs receiving 
Figure 2. Cyclic flow variation (CFV) restoration rate in the dif- 
ferent groups after infusion of epinephrine. *p < 0.05 compared with 
Group I. 
Group I Group II Group III 
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Figure 3. Mean coronary Diaod How velocity chaages during the 
different time periods of the study. *p < 0.05 compared with initial 
cyclic flow variations KFV). Control = the time period before 
coronary artery constriction and endothelial injury: EPI = epineph- 
tine; Stenosis = the time period immediately after the coronary 
artery was constricted. 
Figure 4. Representative recordings of hemodynamic changes dur- 
ing the study protocol. Paper speed 0.025 mm/s for la. Ib and Ic and 
0.05 mm/s for IIa, IIb. IIc. IIIa, IIIb and 111~. Abbreviations as in 
Figure I. Arrows represent beginning of drug administration. 
flow variations restored again. although the epi 
infusion rate was increased to I A + 0.1 
fn Grottp iii. 7 (6596’0) of I 1 dogs had c 
restored when the epinephrine infusion rate was i~c~~ase~ to 
0.4 + 0.2 &kg per min.Five of these seven dogs received a 
bolus injection of 0. I mg/kg of LY 53,857 with a 0.05 mg/kg 
per h continuous infusion, and ic flow variations were 
again abolished in all. Cyclic variations were never 
restored again in these five dogs, even wit 
infusion rate as high as 1 .O r: 0.2 I &kg pe 
dogs in Group 818 never had cyclic flow variations restored 
after their abolition by R 68,010; the e ~ne~bri~e infusion 
rate reached I.2 2 0. I2 &kg per min. 
The cyclic flow variati restoration rate was significanti 
lower in dazoxiben- an 68,070-treated dogs (Groups 
and 111) than in SQ 29. 
and p = 0.04. res 
dazoxiben and R reduce the ability o 
restore cyclic flow variations. There was no signi~ca~t 
difference between C_;e frequency of initial and epinephrine- 
restored cyclic flow variations in all 
nadir Wow of epinephrisre-restored cycl 
significantly higher than the initial nadi 
Group 111 dogs (p = 0.01 and p < 0.001. respec 
3 and 4). This indicates that dazoxiben and R 
- 
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¶ow varialioras: 
cyclic Bow variations KFVsl abolis ed t II = 30 min after cyclic 
n af?er cyclic flow vari 
ow variations resloreed = 3 
agents. No cyclic flow variations restored = cyclic flow variations 
not restored by epinephrine after their abolition by dazoxiben and 
LY 53.857 in Group 11 and by 68.070 and LY 53.857 in Group 111. 
uce the severity of cyclic flow variasims restored by 
were similar in eat 
5). ~pj~e~~rine infusion s~~~jfica~~ly increased plasma epi- 
nephrine concentration: in Croup 1 dogs. the concentration 
was 50 times higher than control value after cyclic flow 
variations were restore In Group II and Group 
111 dogs, the epi~e~hr~~ uired to restore cyclic 
flow variations were > 1 rol levels (p = 0.01 and 
p = 0.003, respectively) and were significantly higher than 
those required to restore cyclic flow variations in Group I 
dogs (p = 0.02 and p = 0.02, respectively). 
Among dogs ~~~it~(ttt~ cyclic flow varialiotts restoretl, tha 
plasma e~i~ep~rit~e cotIce~~r(t~i~tns reached high levels. In 
Group II, aa average e~i~ephr~ne concentration of 25. ii 2 3.6 
nglml was obtained in the e dogs in which cyclic 
variations were not restore fter their a~o~~tio~ by da 
ben and the other four dogs in which cyclic flow variations 
were not restored after abolition by LV 53,857 and dazoxi- 
ben. This plasma epinephrine concentration was 500 times 
w 
ve revea’led that 
involved in the development of cyclic 
canine model are a~~re~atin~ platelets on the stenosed artery 
after the injury of endothe~i~m and the release of 
mboxane A2 and serotonin from the aggregating plate- 
lets. leading to further platelet tion and coronary 
artery vasoconstriction. As plat sa~gregate or me- 
cha~ical forces such as gentle 
A, synthetase inhibitors or receptor antagOniStS eliminates 
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Table 1. Hemodynamic Changes in the Four Groups 
HR AOS 
(beats/mitt) (mm Hgt 
AOD 
(mm HeI 
AOM 
(mm Hg) 
0 
Utnn Hg x 
beats/mint 
Group I (n = 17) 
Contiol 
Stenosis 
Initial CFV 
Post SQ 29.548 
Epi CFV (n = 12) 
Group II 01 = II) 
Control 
Stenosis 
Initial CFV 
Post dazoxiben 
Epi CFV (11 (n = 4) 
Post LY 53,857 
Epi CFV (21 
Group Ill (n = I I) 
Control 
Stenosis 
Initial CFV 
Post R 68.070 
Epi CFV (I) fn = 51 
Post LY 53.857 
Epi CFV (2) 
Group IV In = 6) 
Control 
Stenosis 
Initial CFV 
Post ASA f R 
68.070 
146 I 7 I31 2 4 
145 -+ 6 129 + 4 
141 f 4 I25 + 4 
I37 2 6 127 2 3 
139 2 7 133 + 6 
I41 ?. 4 
142 + 4 
138 + 6 
13626 
142 * 4 
I42 + 5 
167 9 7 
139 + 6 
I41 + 5 
I35 -c 5 
132 k 4 
I71 1: I3 
136 + 6 
I80 + I2* 
139 -+ 4 
141 + 4 
138 + 5 
I35 + 5 
138 + 7 
I39 d 9 
I58 f II 
138 -+ 4 
137 + 4 
I37 t 6 
137 + 4 
138 rL IO 
I26 ‘c 4 
I88 z 6* 
126 + 4 
I25 r 4 
124 2 4 
118 -+ 5 
139 + IO 
140 9 9 
I39 2 8 
I35 2 H 
107 % 3 
lo6 t 3 
IO1 ?r 4 
IO1 ? 3 
93 + 5 
II7 Z.6 
11425 
109 + 5 
IO3 r 4 
103 ?: II 
75 r 5 
113 + 7 
II0 -+ 4 
107 c 4 
I04 c 6 
IO! 2 4 
86 c 7 
74 Z! 2+ 
I24 + IO 
II3 + 8 
:I4 r 8 
II4 ?1 8 
I96 + 7 
II5 + 4 
II3 -+ 3 
I09 r 4 
1102 3 
lo6 + 5 
124 2 5 
I23 -c 5 
118 ?- 5 
II2 t 4 
126 2 I2 
93 2 5 
135 2 a+ 
119 _c 4 
II7 t 4 
II5 r6 
II4 + 4 
I03 + 8 
91 k 3: 
14s t 8 
I21 ?Z 8 
123 = 8 
122 2 7 
115 - 7 
19.318 c 1.307 
18.737 -c 887 
17,680 Z 863 
17.488 + 909 
18.795 + 1.636 
19.601 + 1.070 
20.066 t I.081 
18.749 c I.212 
18.034 + 1.084 
24.381 k 2.183 
18.427 ?_- I.121 
29.909 + I.572 
19.247 + 781 
19.292 + 620 
18.776 + 904 
18.369 + 704 
18.926 t 1.683 
17.252 -+ 938 
29.885 ?: 2.502 
17.583 + I.569 
17.637 + I.537 
17.261 + 1.226 
15.735 f I.451 
*p < 0.01 and tp < 0.0s Tompared with control value. AOD = diastolic aortic pressure: AOM = mean aortic 
pressure: AOS = systolic aortic pressure: ASA = aspirin: CFV = cyclic flow variation: Epi = epinephrine: HR = 
heart rate; LY 53.857 = a serotonin S, receptor antagonist: Post = after: PRO = heart rate x systolic aortic pressure; 
R 68.070 = dual thromboxane synthetase inhibitor and receptor antagonist: SQ 29.548 = a thromboxane 
A,-prosqlandin Hz receptor antagonist: (1) and (21 = see Figure 5. 
cyclic flow variations in approximately 70% of treated dogs 
(13.15). This is associated with significant reductions in 
plasma thromboxane B, levels and less platelet deposition 
on the stenosed artery walls (13,15-17). In the present study, 
cyclic flow variations were abolished in 71% of dogs treated 
with SQ 29,548, the thromboxane A,-prostaglandin Hz re- 
ceptor antagonist, and 82% of dogs treated with dazoxiben, 
Table 2. Serum Thromboxane BzConcentrations f g/mll in 
Groups 111 and IV 
Group 111 Group IV 
Control 2.2 -+ I.0 2.0 2 0.5 
Treated 0.8 ? 0.6 0.9 f 0.6 
Thromboxane BZ is the stable metabolite of thromboxane A,. Control = 
befm the start of cyclic flow variations; Treated = IO min after the 
administration of R 68.070. the combined thromboxane synthetase inhibitor 
and receptor antagonist. 
the thromboxane A2 synthetase inhibitor. These results are 
consistent with our previous studies (13,151. 
The agent R 68,070, (El-5-[(((3-pyridinylI[3-(trifluoromethyt) 
phenyl] methylen] aminoloxy! pentanoic acid (Janssen Re- 
search Foundation). is a newly developed antiplatelet agent 
that combines the actions of thromboxane A1 synthetase 
inhibitor and thromboxane AZ-prostaglandin Hz receptor 
antagonist in one molecule. Preliminary studies (27,28) have 
shown that this drug inhibits human platelet aggregation 
induced by U 46,619, collagen and adenosine diphosphate 
(ADP) without affecting the activity of cyclooxygenase, 
prostacyclin synthetase and 5,12,15Jipoxygenase. When 
R 68,070 is administered at low dose (0.3 mg/kg) to dogs in 
vivo, it blocks only the synthesis of tbromboxane Al; at a 
higher dose (5 mglkg). it blocks both thromboxane AZ 
synthesis and receptor activation. Studies from this labora- 
mate. 
concentration of 
by dazoxiben or R 68.070 than in those with variations 
abolished by SQ 29,548. This indicates that dazoxiben and R 
68,070 provide more protection against epi ~me-induced 
cyclic flow variations than SQ 29.548. in previous 
studies (21,22,27.28). dazoxiben and 68,070 increase the 
synthesis of prostacyclin. A protective effect against epi- 
nephrine-induced cyclic flow variations may be associated 
with increased prostacyclin concentrations. hen the sero- 
tonin S, receptor a~ta~~~ 53.857 was given in comb’ 
nation &th dazoxiben or 70. e~i~e~bri~e infusion di 
not restore the flow variations abolished by the 
is suggests that a 
Backing the action o 
thromboxane AZ and serotonin and promoting the produc- 
tion of prostacyclin. 
Our previous studies (91 revealed that epinephrine re- 
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